Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
7.23
-0.17 (-2.23%)
Aug 4, 2025, 4:00 PM - Market closed
ShockWave Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for ShockWave Medical stock has a target of 13, which predicts a 79.93% increase from the current stock price of 7.23.
Price Target: $13.00 (+79.93%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for ShockWave Medical is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|
| Strong Buy | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Noble Capital Markets | Noble Capital Markets | Buy Initiates $13 | Buy | Initiates | $13 | +79.93% | Jan 22, 2025 |
| Small Cap Consumer Research | Small Cap Consumer Research | Strong Buy Maintains $16 → $18 | Strong Buy | Maintains | $16 → $18 | +150.52% | Jul 26, 2022 |
Financial Forecast
Revenue This Year
14.14M
from 2.14M
Increased by 560.75%
Revenue Next Year
97.32M
from 14.14M
Increased by 588.39%
EPS This Year
-0.57
from -0.99
EPS Next Year
1.48
from -0.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 14.6M | 100.2M | 189.4M |
| Avg | 14.1M | 97.3M | 184.0M |
| Low | 13.6M | 93.5M | 176.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 580.2% | 608.6% | 94.7% |
| Avg | 560.8% | 588.4% | 89.1% |
| Low | 534.9% | 561.4% | 81.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.59 | 1.52 | 3.84 |
| Avg | -0.57 | 1.48 | 3.73 |
| Low | -0.55 | 1.42 | 3.59 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | 159.8% |
| Avg | - | - | 152.4% |
| Low | - | - | 142.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.